trending Market Intelligence /marketintelligence/en/news-insights/trending/59gbv72k5ak5_n5qq0fnfg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Immunomedics prices $276M common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Immunomedics prices $276M common stock offering

Immunomedics Inc. priced its public offering of common stock to raise about $276 million in gross proceeds.

The Morris Plains, N.J.-based biopharmaceutical company is issuing 11.5 million common shares at $24 apiece.

Immunomedics granted the underwriters an option to buy up to an additional 1,725,000 shares.

The company plans to use net proceeds from the offering for accelerating the clinical development program of sacituzumab govitecan for solid cancers, manufacturing process improvements, and for working capital and general corporate purposes.

The offering is expected to close June 15, subject to customary closing conditions.

Morgan Stanley, Cowen and Jefferies are acting as book-running managers, while Wells Fargo Securities is serving as lead manager for the offering.